Trials / Active Not Recruiting
Active Not RecruitingNCT03282344
A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma
A Pilot Study of NKTR-214 and Nivolumab in Selected Patients With Locally Advanced/Metastatic Sarcoma (CA209-9EM)
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 88 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to test any good and bad effects of the combination of study drugs called NKTR-214 and nivolumab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | NKTR-214 | 0.006mg/kg IV on day 1 and every 3 weeks thereafter will be an intravenous (IV) infusion administered over 30 (±5) minutes every 3 weeks. |
| DRUG | Nivolumab | 360mg (flat dose) IV infusion administered over 30 (±5) minutes every 3 weeks. |
Timeline
- Start date
- 2017-09-12
- Primary completion
- 2026-09-01
- Completion
- 2026-09-01
- First posted
- 2017-09-13
- Last updated
- 2025-10-01
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03282344. Inclusion in this directory is not an endorsement.